Consultant-led education

Treosulfan and busulfan in the context of assessing VOD risk

Dr Manos Nikolousis analyses the impact of treosulfan and busulfan on VOD risk and in relation to other treatment factors.

Topics:

Risk assessment and monitoring

ADVERSE EVENTS REPORTING

Adverse events should be reported. Reporting forms and information for the UK can be found at: https://yellowcard.mhra.gov.uk/

For Ireland, reporting forms and information can be found at: www.hpra.ie

Adverse events should also be reported to Jazz Pharmaceuticals at: AEreporting@jazzpharma.com

Defitelio® is indicated for the treatment of severe hepatic veno-occlusive disease (VOD) also known as sinusoidal obstruction syndrome (SOS) in haematopoietic stem-cell transplantation (HSCT) therapy. It is indicated in adults and in adolescents, children and infants over 1 month of age.